The present disclosure relates to cleavable conjugates (for example, particle-based or antibody-based conjugates) of TLR7/8 agonists (for example, 1H-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating linker. The present disclosure also related to methods for preparation of the cleavable conjugates, uses thereof for stimulating an effective immune response, and uses thereof for the treatment of cancer.

A drug carrier, a drug structure, a purpose of the same, a method of making the same, and a method of using the same to inhibit H. pylori are revealed. The drug carrier includes a negatively charged polymer, chitosan and magnetic particles. The purpose of the drug carrier is to make a drug for inhibiting H. pylori. The drug structure includes a negatively charged polymer, chitosan, magnetic particles and an active ingredient. The method of making the drug structure includes mixing the negatively charged polymer solution, the chitosan solution, the magnetic particles and the active ingredient solution to form an initial solution and allowing ingredients in the initial solution to react and thereby form drug structure particles. The method of using the drug structure to inhibit H pylori includes administering the drug structure to an H. pylori colony. The drug carrier and drug structure demonstrate enhanced therapeutic efficacy.

A cell-nanoparticle drug delivery system includes mesenchymal stem cells and gadolinium-based agent-loaded magnetic nanoparticles which are internalized into the mesenchymal stem cells. Each of the gadolinium-based agent-loaded magnetic nanoparticles includes a core that is loaded with gadolinium-based agent and that includes a fucoidan-based inner core layer with the fucoidan non-covalently bound to the gadolinium-based agent, and a shell which includes superparamagnetic iron oxide-based inner shell layer with the superparamagnetic iron oxide bound to the gadolinium-based agent through electrical attraction, and an outer shell layer made of fucoidan and polyvinyl alcohol. Methods for inhibiting the growth of tumor cells and diagnosing the tumor cells in a subject using the cell-nanoparticle drug delivery system are also provided.

The invention discloses a composition comprising surface modified iron oxide nanoparticles with citric acid modified cyclodextrin with a hydrodynamic diameter of less than 10 nm and a hydrophobic molecule.

The composition finds use in targeted delivery of a hydrophobic drug and as contrast agent in imaging applications.

The invention provides novel compounds, pharmaceutical compositions and methods of preparation and therapeutic use thereof. The invention also provides novel gel compositions comprising hyaluronic acid (HA) polymers that are crosslinked with appropriate reversible crosslinkers and encapsulation of therapeutics or other payloads in such gel composition and nanoparticles thereof. The invention also relates to targeted delivery of such gel compositions and nanoparticles to specific cell types in a controllable delivery and release. The invention additionally relates to methods of therapeutic use of such gel compositions and nanoparticles in treatment of various diseases and conditions. The invention further relates to methods of preparation of the gel compositions and nanoparticles disclosed herein.

A drug carrier, a drug structure, a purpose of the same, a method of making the same, and a method of using the same to inhibit H. pylori are revealed. The drug carrier includes a negatively charged polymer, chitosan and magnetic particles. The purpose of the drug carrier is to make a drug for inhibiting H. pylori. The drug structure includes a negatively charged polymer, chitosan, magnetic particles and an active ingredient. The method of making the drug structure includes mixing the negatively charged polymer solution, the chitosan solution, the magnetic particles and the active ingredient solution to form an initial solution and allowing ingredients in the initial solution to react and thereby form drug structure particles. The method of using the drug structure to inhibit H pylori includes administering the drug structure to an H. pylori colony. The drug carrier and drug structure demonstrate enhanced therapeutic efficacy.

This application discloses the approach of synthesizing cellulose acetate nanoparticles and rods which may have a chemically functionalized surface and an encapsulated cargo load. Functionalization and/or loading of the cargo are made through a physical mixing of the functionalizing and/or cargo components in the synthesizing bath. This can result in particles with functionalized surfaces with various functional groups, as well as active cargo load encapsulated in the particles. The encapsulated cargo includes but is not limited to biologically, chemically, and optically active substances.

This disclosure provides nano-scale Artificial Antigen Presenting Cells (aAPC), which deliver stimulatory signals to lymphocytes, including cytotoxic lymphocytes, for use as a powerful tool for immunotherapy.

Provided are methods relating to the treatment of cancer with a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101 in combination with an inhibitor of the tryptophan metabolism pathway, e.g., an indoleamine-2,3-dioxygenase (IDO) inhibitor or a tryptophan-2, 3-dioxygenase (TDO) inhibitor.

The present invention relates to biofunctionalized nanoparticles and uses thereof in adoptive cell therapy. In particular, the present invention relates to a nanoparticle comprising an amount of at least one antigen and an amount of at least one antibody having specificity for a B cell receptor wherein the antigen and antibody are attached to the surface of the nanoparticle.